<DOC>
	<DOC>NCT00160199</DOC>
	<brief_summary>To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea</brief_summary>
	<brief_title>Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Amenorrhea</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Women with secondary amenorrhea Normal serum Dehydroepiandrosterone (DHEA), prolactin, testosterone, Thyroid Stimulating Hormone (TSH) and thyroxine Primary amenorrhea Other medical conditions resulting in amenorrhea (e.g. Asherman's syndrome) Peanut allergy Allergy to progestational steroids</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>To collect additional data on 300 and 400 mg doses of PROMETRIUM in women with secondary amenorrhea</keyword>
</DOC>